AJG Author Presentation Series

AJG Presentation Series Icon Welcome to a series of lecture presentations featuring recent articles published in The American Journal of Gastroenterology, in which the authors review key findings of their research.

December 2013

Dr. Laura TargownikInfectious and Malignant Complications of TNF Inhibitor Therapy in IBD
A presentation by Laura E. Targownik, MD, MSHS

On behalf of her co-author, Laura E. Targownik, MD, MSHS, reviews the study design and key findings of their article entitled “Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD,” which was published in the December 2013 issue of AJG. This narrative review examines evidence from studies evaluating the association of TNF inhibitors with overall and specific infections, such as tuberculosis, hepatitis, herpes, and varicella, and with overall and specific malignancies, such as nonmelanoma skin cancer and non-Hodgkin’s lymphoma. While risks of specific infections and malignancies may be slightly increased with TNF inhibitor use, the overall risk of infection and malignancy appears to be minimal.

Click here to view the presentation.
Click here to read the AJG article.

November 2013

Dr. Anthony DeBenedetIntraprocedural Quality in Endoscopic Retrograde Cholangiopancreatography:
A Meta-Analysis

A presentation by Anthony T. DeBenedet, MD, MSc

On behalf of his co-authors, Anthony T. DeBenedet, MD, MSc, reviews the study design and key findings of their article entitled “Intraprocedural Quality in Endoscopic Retrograde Cholangiopancreatography: A Meta-Analysis,” which was published in the November 2013 issue of AJG. This study used 52 articles from the published literature to compare current endoscopic retrograde cholangiopancreatography (ERCP) intraprocedural performance to the quality indicator targets set by the ACG/ASGE taskforce in 2006. Comparisons were also made across healthcare settings, study designs, and trainee participation. All procedures except precut utilization and common bile duct stone extraction met or exceeded the set targets.

Click here to view the presentation.
Click here to read the AJG article.

September 2013

Dr. Praveen SharmaA Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy
A presentation by Praveen Sharma, MD, DM

On behalf of his co-authors, Praveen Sharma, MD, DM, reviews the study design and key findings of their article entitled “A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy,” which was published in the September 2013 issue of AJG. This study randomized 120 patients with overt HE into two groups: one with lactulose plus rifaximin and the other with lactulose plus placebo. The primary end point was complete reversal of HE and the secondary end points were mortality and hospital stay. The patients treated with both lactulose and rifaximin fared better on all three endpoints.

Click here to view the presentation.
Click here to read the AJG article.

August 2013

Dr. Rune ErichsenCharacteristics and Survival of Interval and Sporadic Colorectal Cancer Patients: A Nationwide Population-Based Cohort Study
A presentation by Rune Erichsen, MD

On behalf of his co-authors, Rune Erichsen, MD reviews the study design and key findings of their article entitled “Characteristics and Survival of Interval and Sporadic Colorectal Cancer Patients: A Nationwide Population-Based Cohort Study,” which was published in the August 2013 issue of AJG. This cohort study from Danish population-based medical registries investigated patients with “interval” CRC diagnosed within 1-5 years of a colonoscopy, and compared them with cases with colonoscopy ≥10 years before diagnosis and to “sporadic” CRCs with no colonoscopy before diagnosis. Comorbidities and survival rates were compared among the groups, and findings suggest that the majority of these interval cancers represented missed lesions rather than aggressively growing cancers.

Click here to view the presentation.
Click here to read the AJG article.

July 2013

Dr. Ashwin AnanthakrishnanImpact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases
A presentation by Ashwin N. Ananthakrishnan, MD, MPH

On behalf of his co-authors, Ashwin N. Ananthakrishnan, MD, MPH, reviews the study design and key findings of their article entitled “Impact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases,” which was published in the July 2013 issue of AJG. This case-control study from two tertiary referral centers examined whether patients with coexisting celiac disease present a unique phenotype of IBD and whether the frequency of co-occurrence of celiac disease and IBD differs in comparison with other autoimmune disorders.

Click here to view the presentation.
Click here to read the AJG article.

March 2013

Dr. Philip KatzDay-Before Administration of a Novel, Dual-Action, Low-Volume Bowel Cleanser for Colonoscopy: Efficacy and Safety Results from the SEE CLEAR II Study
A presentation by Philip O. Katz, MD, FACG

Philip O. Katz, MD, FACG, reviews the study design and key findings of his article entitled “A Dual-Action, Low-Volume Bowel Cleanser Administered the Day Before Colonoscopy: Results from the SEE CLEAR II Study,” which was published in the March 2013 issue of AJG. This phase 3, randomized, assessor-blinded, non-inferiority study investigated the efficacy, safety, and tolerability of day-before administration of P/MC vs. 2 L PEG-3350 and two 5 mg bisacodyl tablets in adult patients preparing for colonoscopy.

Click here to view the presentation.
Click here to read the AJG article.